SV2002000036A - OPEN ACID INHIBITORS AND REDUCTASE DIHYDROXYL SALTS HMG-CO-A REF.B.11111 / RM / MA - Google Patents

OPEN ACID INHIBITORS AND REDUCTASE DIHYDROXYL SALTS HMG-CO-A REF.B.11111 / RM / MA

Info

Publication number
SV2002000036A
SV2002000036A SV2000000036A SV2000000036A SV2002000036A SV 2002000036 A SV2002000036 A SV 2002000036A SV 2000000036 A SV2000000036 A SV 2000000036A SV 2000000036 A SV2000000036 A SV 2000000036A SV 2002000036 A SV2002000036 A SV 2002000036A
Authority
SV
El Salvador
Prior art keywords
hmg
dihydroxyl
reductase
ref
salts
Prior art date
Application number
SV2000000036A
Other languages
Spanish (es)
Inventor
Edward J J Grabowski
Richard D Tillyer
Paul J Reider
Jose M Vega
Feng Xu
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SV2002000036A publication Critical patent/SV2002000036A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

EL PRESENTE INVENTO OFRECE METODOS Y COMPOSICIONES FARMACEUTICAS PARA LA INHIBICION DE REDUCTASA HMG-CoA, ASI COMO EL TRATAMIENTO Y/O REDUCCION DEL RIESGO DE ENFERMEDADES Y CONDICIONES QUE AFECTAN LA INHIBICION DE REDUCTASA HMG-CoA, QUE COMPRENDE LA ADMINISTRACION ORAL DE UNA CANTIDAD EFECTIVA TERAPEUTICAMENTE DE UN COMPUESTO SELECCIONADO DE UNA ESTATINA DE ACIDO ABIERTO DE DIHIDROXILO Y UNA SAL O ESTER CORRESPONDIENTE FARMACEUTICAMENTE ACEPTABLE EN FORMA DE DOSIS FARMACEUTICA DE LIBERACION RETRASADA A UN PACIENTE QUE NECESITE DICHO TRATAMIENTO, DONDE UNA IMPORTANTE LIBERACION DEL COMPUESTO DE LA DOSIS SE RETRASA HASTA QUE LA DOSIS PASE AL ESTOMAGO.THE PRESENT INVENTION OFFERS PHARMACEUTICAL METHODS AND COMPOSITIONS FOR THE INHIBITION OF HMG-CoA REDUCTION, AS WELL AS THE TREATMENT AND / OR REDUCTION OF THE RISK OF DISEASES AND CONDITIONS AFFECTING THE INHIBITION OF HMG-CoATIA EFFECTIVE ADMINISTRATION OF A REDUCTION THERAPEUTICALLY OF A SELECTED COMPOSITE OF AN OPEN ACID STATIN OF DIHYDROXYL AND A PHARMACEUTICALLY ACCEPTABLE CORRESPONDING SALT OR ESTER IN THE FORM OF A PHARMACEUTICAL DOSE OF RELEASE DELAYED TO A PATIENT THAT NEEDS SUCH TREATMENT DIFFUSED DOSE PASS TO STOMACH.

SV2000000036A 1999-03-08 2000-03-08 OPEN ACID INHIBITORS AND REDUCTASE DIHYDROXYL SALTS HMG-CO-A REF.B.11111 / RM / MA SV2002000036A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12322799P 1999-03-08 1999-03-08
US26474499A 1999-03-09 1999-03-09
PCT/US2000/002626 WO2000053173A1 (en) 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors

Publications (1)

Publication Number Publication Date
SV2002000036A true SV2002000036A (en) 2002-02-05

Family

ID=26821357

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2000000036A SV2002000036A (en) 1999-03-08 2000-03-08 OPEN ACID INHIBITORS AND REDUCTASE DIHYDROXYL SALTS HMG-CO-A REF.B.11111 / RM / MA

Country Status (9)

Country Link
EP (1) EP1161236A1 (en)
JP (2) JP2002538202A (en)
AR (1) AR022856A1 (en)
AU (1) AU2866400A (en)
CA (1) CA2364253A1 (en)
CO (1) CO5150193A1 (en)
PE (1) PE20001559A1 (en)
SV (1) SV2002000036A (en)
WO (1) WO2000053173A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523948A (en) * 1999-11-04 2003-08-12 アンドルクス コーポレーション Treatment of amyloid β precursor disorder
EP1324972A4 (en) * 2000-09-06 2004-06-30 Merck & Co Inc Dihydroxy open-acid salt of simvastatin
SK4112003A3 (en) * 2000-10-12 2004-01-08 Nissan Chemical Ind Ltd Preventives and remedies for complications of diabetes
KR20040026705A (en) 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 Processes for preparing calcium salt forms of statins
EP1425287A4 (en) * 2001-08-16 2005-09-07 Teva Pharma Processes for preparing calcium salt forms of statins
AU2003206251B2 (en) * 2002-01-09 2008-03-13 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AR040588A1 (en) 2002-07-26 2005-04-13 Schering Corp PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
DE602004020649D1 (en) * 2003-11-07 2009-05-28 Jj Pharma Inc HDL REINFORCING COMBINATION THERAPY COMPLEXES
WO2015055857A1 (en) * 2013-10-18 2015-04-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Rny-derived small rnas as biomarkers for atherosclerosis-related disorders
EP3624789B1 (en) 2017-05-15 2024-09-25 University of Cincinnati Compositions comprising metabolites of simvastatin for use in repairing or retarding damage to avascular cartilaginous tissue by direct administration to the avascular tissue
CN113134086B (en) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 Pharmaceutical composition for reducing blood fat

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU217629B (en) * 1991-12-12 2000-03-28 Novartis Ag. Process for producing stabilized pharmaceutical compositions comprising fluvastatin
DE122011000014I1 (en) * 1995-12-22 2011-11-03 Kowa Co Pharmaceutical composition stabilized with a basic medium.
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
JP2000256191A (en) 2000-09-19
PE20001559A1 (en) 2001-01-16
JP2002538202A (en) 2002-11-12
EP1161236A1 (en) 2001-12-12
CA2364253A1 (en) 2000-09-14
WO2000053173A1 (en) 2000-09-14
AR022856A1 (en) 2002-09-04
AU2866400A (en) 2000-09-28
CO5150193A1 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
SV2002000035A (en) OPEN ACID INHIBITORS AND REDUCTASE DIHYDROXYL SALTS HMG-CO-A REF.B.11121 / RM / TA
SV2002000036A (en) OPEN ACID INHIBITORS AND REDUCTASE DIHYDROXYL SALTS HMG-CO-A REF.B.11111 / RM / MA
UA90858C2 (en) Controlled-release formulations containing vardenafil
DOP2005000039A (en) HYDROCHLORIDE OF [4- (5-AMINOMETIL-2-FLUORO-PHENYL) - PIPERIDIN-1-IL] - (4-BOMO-3-METHYL-5-PROPOXI-TIOFEN-2-IL) -METANONE AS AN INHIBITOR OF THE MASTOCYT TRIPTASE
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
NZ514574A (en) Novel method of treatment
CZ309247B6 (en) 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
CO5570677A2 (en) QUINOLINILPIRROLOPIRAZOLES
MXPA04009352A (en) COMBINATION THERAPY FOR THE TREATMENT OF PARKINSONaCOES DISEASE WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S).
WO2007126964A3 (en) Kinase inhibitors
WO2005016326A3 (en) Analogs of thalidomide as potential angiogenesis inhibitors
WO2003065982A3 (en) Engineering absorption of therapeutic compounds via colonic transporters
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
RU2008103617A (en) BISPHOSPHONIC ACIDS INTENDED FOR TREATMENT AND PREVENTION OF OSTEOPOROSIS
UA89035C2 (en) Hydroxamic acid esters and pharmaceutical use thereof
CY1106763T1 (en) PREVENTIVE OR THERAPEUTIC MEANS FOR INFLAMMATORY BOWEL DISEASES
EP1750703A4 (en) Method for reducing gastrointestinal toxicity due to the administration of tegafur
IL300151A (en) Combinations for the treatment of cancer
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
PT1150704E (en) MELAGATRAN FOR THE TREATMENT OF INFLAMMATION
NO20031410L (en) Use of distamycin derivatives for the manufacture of drugs
MX2022006052A (en) Caspase 6 inhibitors and uses thereof.
AR039162A1 (en) VENLAFAXINA FORMULATIONS OF EXTENDED LIBERATION